Dofetilide (Tikosyn) Considerations for Use*. US/FDA Special Notes. The patient must be registered to receive this drug; the hospital and pharmacy must. Easy to read FDA package insert, drug facts, dosage and administration, and adverse effects for Tikosyn (Dofetilide). (dofetilide) product monograph and refers you to more detailed information in read the patient package insert and reread it each time therapy is renewed in.
|Published (Last):||5 May 2015|
|PDF File Size:||11.22 Mb|
|ePub File Size:||14.13 Mb|
|Price:||Free* [*Free Regsitration Required]|
Major Drugs that are actively secreted via cationic tubular secretion, such as triamterene, should be co-administered with caution with dofetilide since they could increase dofetilide plasma concentrations via potential competition for renal cationic secretion. Erythromycin, a potent CYP3A4 inhibitor, significantly increases dofetilide plasma concentrations.
Prolongation of the QT interval has also been reported with lenvatinib therapy. Chlorpromazine is specifically associated with an established risk of QT prolongation and TdP; case reports have included patients receiving therapeutic doses of chlorpromazine. Because of the potential for TdP, use of vardenafil with dofetilide is contraindicated.
Tikosyn (dofetilide) dose, indications, adverse effects, interactions from
Because of the potential for TdP, concurrent use is contraindicated. Severe Because of the increased risk for QT prolongation and torsade de pointes TdPthe use of dofetilide with ondansetron is contraindicated. Efavirenz has also been associated with QT prolongation. Continue dosage at discharge as from initial dosage titration. Because of the potential for TdP, use of dofetilide with telavancin is contraindicated Telithromycin: The maximal change in the QTc interval occurs approximately 5 to 10 hours following oral administration of gemifloxacin.
Although drug interaction studies have not been conducted, the serum concentrations of dofetilide may be increased with concomitant administration of amprenavir. Bepridil has Class I antiarrhythmic properties and is associated with a well-established risk of QT prolongation and TdP.
This interaction is proposed to occur primarily by inhibition of cationic renal tubular secretion of dofetilide by ketoconazole, however, inhibition of CYP 3A4 metabolism may also contribute. Severe Based on electrophysiology studies performed by the manufacturer, alfuzosin has a slight effect to prolong the QT interval.
Dofetilide is not effective in patients with paroxysmal atrial fibrillation. Severe Because of the potential for torsade de pointes TdPuse of panobinostat with dofetilide is contraindicated.
Halogenated anesthetics can prolong the QT interval. Severe Tacrolimus prolongs the QTc interval. Before administering macimorelin, discontinue use of dofetilide and allow a sufficient washout dofetilude to pass.
There was a problem providing the content you requested
Severe Coadministration of ivosidenib with dofetilide is contraindicated due to an increased risk of QT prolongation.
Severe Because of the potential for torsade de pointes TdPconcurrent use of dofetilide and haloperidol is contraindicated. Severe Ezogabine has been associated with QT prolongation. In addition, there are post-marketing reports of torsade de pointes TdP.
The QT prolongation appeared less with alfuzosin 10 mg than with 40 mg. However, due to the lack of clinical data and the potential for torsade de pointes TdPuse of dofetilide with mefloquine is contraindicated. Ceritinib also causes concentration-dependent prolongation of the QT interval.
Severe Concurrent use of dofetilide with ketoconazole is contraindicated due to the risk of serious cardiovascular events. Clinicians should also evaluate any concomitant drug therapy for the potential to decrease the renal elimination of dofetilide. Hypokalemia should be corrected before initiation of therapy. Because of the potential for TdP, dofetilide is contraindicated with any drug associated with QT prolongation. Because of the unpredictable pharmacokinetics of amiodarone, dofetilide should not be initiated following amiodarone therapy until amiodarone plasma levels are below 0.
In vitro, dofetilide is a CYP3A4 substrate, although it has low affinity for this isoenzyme. Although no study specifically investigated this risk, in post-trial analyses, no increase in mortality was observed in females receiving dofetilide vs.
Dofetilide, a Class III antiarrhythmic, is proarrhythmic and may induce or worsen cardiac arrhythmias.
Dofetilide increases the monophasic action potential duration in a predictable, concentration-dependent manner, primarily due to delayed repolarization. Severe Because of the potential for torsade de pointes TdPuse of midostaurin with dofetilide is contraindicated. Bictegravir; Emtricitabine; Tenofovir Alafenamide: Severe Degarelix can cause QT prolongation.
Posaconazole is a potent inhibitor of CYP3A4, an isoenzyme responsible for a portion of the metabolism of dofetilide. Severe Because of the potential for TdP, concurrent use of mifepristone and dofetilide is contraindicated. Major Drugs that are actively secreted via cationic tubular secretion, such as amiloride, should be co-administered with caution with dofetilide since they could increase dofetilide plasma concentrations via potential competition for renal cationic secretion.
Rare cases of TdP have been spontaneously reported during postmarketing surveillance in patients receiving levofloxacin. Droperidol administration is associated with an established risk for QT prolongation and TdP. Dofetilise should observe patients closely if St. It is not known if hemodialysis removes dofetilide from plasma.
Severe Because of the potential for torsade de pointes TdPuse of ribociclib with dofetilide is contraindicated. Severe Because of the potential for torsades de pointes TdPconcurrent use of artemether; lumefantrine and dofetilide is contraindicated.
Consider the benefits of breast-feeding, the risk of potential infant drug exposure, and the risk of an untreated or inadequately ;ackage condition.